DNA lipid complex gene delivery systems - Valentis
Latest Information Update: 21 May 2007
At a glance
- Originator Nonindustrial source; Valentis
- Developer DSM; Valentis
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Coronary artery restenosis; Cystic fibrosis; Head and neck cancer; Ischaemic heart disorders; Osteoarthritis; Peripheral vascular disorders; Rheumatoid arthritis; Solid tumours; Transplant rejection